Stocktoria
iSpecimen Inc. ISPC
Nasdaq · XNAS · stock · Services-Commercial Physical & Biological Research · website · IPO 2021-06-17
iSpecimen Inc. statistics & valuation
Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else is from filings.
Key ratios (by fiscal year)
| Ratio | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Operating margin | -465.4% | -137.0% | -112.5% | -97.9% | -53.2% |
| Net margin | -543.7% | -134.5% | -111.8% | -98.5% | -80.5% |
| FCF margin | -219.9% | -89.3% | -58.7% | -58.0% | -95.8% |
| Return on assets | -110.0% | -133.7% | -70.2% | -41.6% | -25.1% |
| Return on equity | -339.6% | -377.5% | -113.9% | -50.4% | -30.1% |
| Debt / equity | — | — | — | — | 0.11× |
| Current ratio | 1.12 | 0.62 | 1.36 | 4.60 | 13.15 |
| Revenue growth | -79.2% | -6.4% | -4.6% | -6.6% | 36.1% |
Source: SEC EDGAR filings · CIK 0001558569 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.